Filing Flows › Comparisons › OTLC vs COYA
Oncotelic Therapeutics vs Coya Therapeutics: OTLC and COYA compared
Oncotelic Therapeutics is the larger company: $250K of revenue in its latest quarter (Q2 2026) against $244K for Coya Therapeutics (Q2 2026).
Where the money goes: OTLC and COYA
Oncotelic Therapeutics (OTLC) · Q2 2026
Oncotelic Therapeutics, Q2 2026: revenue $250K, operating margin -337.4%, net earnings $341K, operating cash flow −$92K. The chart follows the revenue to costs, profit and cash.
Coya Therapeutics (COYA) · Q2 2026
Coya Therapeutics, Q2 2026: revenue $244K (+49% year over year), net loss $6.6M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
| Oncotelic Therapeutics (OTLC) | Coya Therapeutics (COYA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $250K | $244K |
| Revenue growth, Y/Y | — | +49% |
| Operating margin | -337.4% | n/m |
| Net earnings | $341K | −$6.6M |
| Net margin | 136.4% | — |
| Operating cash flow | −$92K | −$7.4M |
Questions
Which is bigger, Oncotelic Therapeutics or Coya Therapeutics?
Oncotelic Therapeutics is the larger company: $250K of revenue in its latest quarter (Q2 2026) against $244K for Coya Therapeutics (Q2 2026).
More: Oncotelic Therapeutics earnings · how Oncotelic Therapeutics makes money · Coya Therapeutics earnings · how Coya Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.